Please ensure Javascript is enabled for purposes of website accessibility

Is It Time to Buy the Dow Jones' 3 Worst-Performing February Stocks?

By James Brumley - Mar 3, 2021 at 9:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of Apple, Walmart, and Amgen didn't stumble for the reason most stocks usually sell off.

February was another good month for blue chip stocks, with the Dow Jones Industrial Average gaining 3% despite a sizable setback late last week. It wasn't a great month for every Dow Jones name, however. Walmart (WMT -0.37%), Amgen (AMGN 0.79%), and Apple (AAPL 1.30%) not only lost ground but lost a lot of ground compared to their benchmark index. They fell 7.5%, 6.8%, and 8.1%, respectively.

Smart investors are now rightly wondering if these sell-offs are buying opportunities, but those same investors are also wise to wonder if this weakness is an indication of bigger problems for these companies. Here's a closer look.

Spoiler alert: Most of the losses these three stocks suffered last week have less to do with the respective companies and more to do with January's unusual action.

Man standing on a falling stock chart, watching it move lower.

Image source: Getty Images.


Don't misread the message. Each of these three Dow Jones names did provide investors with a reason to shed their shares.

Amgen, for instance, topped its Q4 sales and earnings estimates but undermined them with lackluster 2021 guidance. Apple's stock struggled following news that Berkshire Hathaway's resident stock-picking guru Warren Buffett pared back the holding company's big stake in the iPhone maker. Walmart shares slumped after the retailer fell short of last quarter's earnings estimate and then warned investors that big spending plans would crimp profit growth this year.

Investors must also bear in mind, however, that all three of these stocks started February with the disadvantage of being well overbought. At one point in January, Apple was up more than 9%. Amgen netted nearly a 5% gain in January and had rallied as much as 13% before rolling over late in the month. Walmart technically lost value during January, but the stock's 50% gain between last March's low and November's peak meant it was vulnerable to profit-taking.

WMT Chart

Performance data by YCharts

And the reason Amgen and Apple did so well in January? Overzealous optimism that life would start moving back toward normal with COVID-19 vaccination seemingly making an impact. Walmart's 2020 rally was rooted in the fact that it's a beneficiary of the pandemic.

...but not out

Largely lost in all this noise and speculation is the fact that nothing's really changed about the companies' long-term prospects. These outfits are still powerhouses in their arenas with lots to look forward to.

Take Walmart's disappointing 2021 outlook for example. Its capital expenditure plans are actually a smart investment in its people and e-commerce presence, which should start to pay proverbial dividends by 2022.

Amgen may have dialed back its outlook and culled a few cancer R&D programs, but this is the same biopharma company that owns blockbuster drugs like Enbrel, Neulasta, Kyprolis, and Epogen just to name a few. It's not for want of things to sell, and with a pipeline of dozens of trials still underway, that's not a risk Amgen is running anytime soon.

And Apple? It remains the biggest, most profitable, most recognized corporation in the world for a reason. It'll be fine. As fellow Fool Trevor Jennewine suggests, Apple enjoys an uncanny ability to address any new market opportunity it wants.

So, yes, in all three cases, this makes their stocks' recent pullbacks an opportunity to step into a company worth owning.

Exceptions to the norm

Given these big swings -- oversized gains followed by last month's sizable setbacks -- it would be easy to conclude COVID-19 is still a huge factor for investors making buy and sell decisions. The difference is that a year ago investors were scrambling to find companies capable of coping with the coronavirus. Now, traders are seemingly clamoring for companies best-positioned to capitalize on the economic recovery.

Take a deeper look at the current trading environment though. Curiously, the big, pandemic-minded swings in the prices of Apple, Amgen, and Walmart are the outliers. Most stocks are moving or starting to move less erratically based on their merits without much respect for the contagion or how quickly we'll put it in the rearview mirror. These three losers should tame themselves soon enough, putting the focus back on their long-term prospects.

It's also worth noting that the analyst community stuck with their buy ratings for all three in February despite plenty of room and reason to impose downgrades.

Connect the dots. This recent weakness makes these Dow Jones stocks all the more attractive to newcomers.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Apple Inc. Stock Quote
Apple Inc.
$139.23 (1.30%) $1.79
Wal-Mart Stores, Inc. Stock Quote
Wal-Mart Stores, Inc.
$121.92 (-0.37%) $0.45
Amgen Inc. Stock Quote
Amgen Inc.
$245.43 (0.79%) $1.92
Berkshire Hathaway Inc. Stock Quote
Berkshire Hathaway Inc.
$411,050.00 (-0.27%) $-1,120.01
Berkshire Hathaway Inc. Stock Quote
Berkshire Hathaway Inc.
$273.49 (-0.14%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.